Fed. Circ. Case May Change Biosimilar IPR Strategy
Biosimilar developers have been aggressive in filing petitions for inter partes reviews of biologics patents before the Patent Trial and Appeal Board, many of them preceding the filing of a marketing...To view the full article, register now.
Already a subscriber? Click here to view full article